Inhibrx, Inc.
NASDAQ:INBX
Overview | Financials
Company Name | Inhibrx, Inc. |
Symbol | INBX |
Currency | USD |
Price | 14.6 |
Market Cap | 211,348,198 |
Dividend Yield | 0% |
52-week-range | 10.8 - 18.95 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Mark Paul Lappe |
Website | https://inhibrx.com |
An error occurred while fetching data.
About Inhibrx, Inc.
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD